Voyager Therapeutics: A Buy Rating on the Back of Strategic Advancements and a Promising Alzheimer’s Candidate

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $30.00.

Patrick Trucchio has given his Buy rating due to a combination of factors surrounding Voyager Therapeutics’ strategic advancements and robust pipeline. Notably, the company’s initiation of Phase 1 dosing for VY-TAU01, an anti-tau monoclonal antibody candidate for Alzheimer’s disease, signals a critical step in proving the drug’s concept. The forward-looking trajectory includes a planned Phase 1b trial aimed at providing initial proof-of-concept data by the second half of 2026, which could substantiate the therapy’s effectiveness in slowing the spread of pathological tau in the brain. Additionally, Voyager’s pipeline is expected to yield at least four Investigational New Drug filings in the next two years across its wholly-owned and partnered programs, further validating its platform.

The analyst’s optimism is also bolstered by Voyager’s financial position, with sufficient capital to support its endeavors well into 2027. This financial stability is critical for reaching various data readouts that could be pivotal for the company. Moreover, preclinical data suggest that VY-TAU01 could lead to a significant reduction in tau spread, which is a promising sign for its potential impact on Alzheimer’s disease progression. The combination of these elements, along with the potential differentiation of VY-TAU01 in the Alzheimer’s market through complementary gene therapy approaches, supports the Buy rating and underscores the potential for Voyager Therapeutics to emerge as a leader in neurogenetic medicines.

According to TipRanks, Trucchio is an analyst with an average return of -12.0% and a 30.17% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sangamo Biosciences, and Gossamer Bio.

In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $18.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Voyager Therapeutics (VYGR) Company Description:

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.